American Journal of Kidney Diseases
Volume 54, Issue 5 , Pages 859-870 , November 2009

Urinary Arsenic Species and CKD in a Taiwanese Population: A Case-Control Study

  • Yu-Mei Hsueh, PhD

      Affiliations

    • Department of Public Health, School of Medicine, Chang Gung Memorial Hospital, and Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
    • Corresponding Author InformationAddress correspondence to Yu-Mei Hsueh, PhD, Department of Public Health, School of Medicine, Taipei Medical University, No. 250 Wu-Hsing St, Taipei 110, Taiwan
    • ,
  • Chi-Jung Chung, MSc

      Affiliations

    • School of Public Health, Chang Gung Memorial Hospital, and Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
    • ,
  • Horng-Sheng Shiue, MD

      Affiliations

    • Department of Chinese Medicine, Chang Gung Memorial Hospital, and Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
    • ,
  • Jin-Bor Chen, MD

      Affiliations

    • Nephrology Division, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan
    • ,
  • Shou-Shan Chiang, MD

      Affiliations

    • Department of Internal Medicine/Nephrology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
    • ,
  • Mo-Hsiung Yang, PhD

      Affiliations

    • Department of Nuclear Science, National Tsing-Hua University, Hsinchu, Taiwan
    • ,
  • Cheng-Wei Tai, MSc

      Affiliations

    • School of Public Health, Chang Gung Memorial Hospital, and Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
    • ,
  • Chien-Tien Su, MD

      Affiliations

    • Department of Family Medicine, Taipei Medical University Hospital, Taipei, Taiwan

Received 17 December 2008 ,Accepted 5 June 2009.

References 

  1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266
  2. Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: A prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371:2173–2182
  3. US Renal Data System: USRDS 2007 Annual Data Report. http://www.usrds.org/Accessed December 31, 2007
  4. Haroun MK, Jaar BG, Hoffman SC, et al. Risk factors for chronic kidney disease: A prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol. 2003;14:2934–2941
  5. Higashikuni Y, Ishizaka N, Ishizaka Y, et al. Relationship between blood pressure and chronic kidney disease in the Japanese population: The lower the better even in individuals without hypertension?. Hypertens Res. 2008;31:213–219
  6. Chen CJ, Kuo TL, Wu MM. Arsenic and cancers. Lancet. 1988;1:414–415
  7. Pu YS, Yang SM, Huang YK, et al. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol Appl Pharmacol. 2007;218:99–106
  8. Hong F, Jin T, Zhang A. Risk assessment on renal dysfunction caused by co-exposure to arsenic and cadmium using benchmark dose calculation in a Chinese population. Biometals. 2004;17:573–580
  9. Meliker JR, Wahl RL, Cameron LL, et al. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: A standardized mortality ratio analysis. Environ Health. 2007;6:4
  10. Thompson DJ. A chemical hypothesis for arsenic methylation in mammals. Chem Biol Interact. 1993;88:89–114
  11. Aposhian HV, Zakharyan RA, Avram MD, et al. A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicol Appl Pharmacol. 2004;198:327–335
  12. Aposhian HV, Aposhian MM. Arsenic toxicology: Five questions. Chem Res Toxicol. 2006;19:1–15
  13. De CS, Ghosh P, Sarma N, et al. Genetic variants associated with arsenic susceptibility: Study of purine nucleoside phosphorylase, arsenic (+3) methyltransferase, and glutathione S-transferase omega genes. Environ Health Perspect. 2008;116:501–505
  14. Kitchin KT. Recent advances in arsenic carcinogenesis: Modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol. 2001;172:249–261
  15. Schmuck EM, Board PG, Whitbread AK, et al. Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of omega class glutathione transferase variants: Implications for arsenic metabolism and the age-at-onset of Alzheimer's and Parkinson's diseases. Pharmacogenet Genomics. 2005;15:493–501
  16. Scibior A, Zaporowska H. Effects of vanadium(V) and/or chromium(III) on l-ascorbic acid and glutathione as well as iron, zinc, and copper levels in rat liver and kidney. J Toxicol Environ Health A. 2007;70:696–704
  17. Nesnow S, Roop BC, Lambert G, et al. DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem Res Toxicol. 2002;15:1627–1634
  18. Stahl W, Sies H. Antioxidant activity of carotenoids. Mol Aspects Med. 2003;24:345–351
  19. Augusti PR, Conterato GM, Somacal S, et al. Effect of lycopene on nephrotoxicity induced by mercuric chloride in rats. Basic Clin Pharmacol Toxicol. 2007;100:398–402
  20. Atessahin A, Ceribasi AO, Yilmaz S. Lycopene, a carotenoid, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rats. Basic Clin Pharmacol Toxicol. 2007;100:372–376
  21. Chen YC, Amarasiriwardena CJ, Hsueh YM, et al. Stability of arsenic species and insoluble arsenic in human urine. Cancer Epidemiol Biomarkers Prev. 2002;11:1427–1433
  22. Hsueh YM, Huang YL, Huang CC, et al. Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health A. 1998;54:431–444
  23. Tseng CH, Huang YK, Huang YL, et al. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol. 2005;206:299–308
  24. Miller KW, Lorr NA, Yang CS. Simultaneous determination of plasma retinol, alpha-tocopherol, lycopene, alpha-carotene, and beta-carotene by high-performance liquid chromatography. Anal Biochem. 1984;138:340–345
  25. Rothman KJ. Modern Epidemiology. Boston, MA: Little Brown; 1986;
  26. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology. 1992;3:452–456
  27. Ratnaike RN. Acute and chronic arsenic toxicity. Postgrad Med J. 2003;79:391–396
  28. Vanholder R, Cornelis R, Dhondt A, et al. The role of trace elements in uraemic toxicity. Nephrol Dial Transplant. 2002;17(suppl 2):S2–S8
  29. Lewis DR, Southwick JW, Ouellet-Hellstrom R, et al. Drinking water arsenic in Utah: A cohort mortality study. Environ Health Perspect. 1999;107:359–365
  30. Tsukamoto H, Parker HR, Gribble DH, et al. Nephrotoxicity of sodium arsenate in dogs. Am J Vet Res. 1983;44:2324–2330
  31. Prasad GV, Rossi NF. Arsenic intoxication associated with tubulointerstitial nephritis. Am J Kidney Dis. 1995;26:373–376
  32. Fowler BA. Mechanisms of kidney cell injury from metals. Environ Health Perspect. 1993;100:57–63
  33. Le XC, Ma M, Cullen WR, et al. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ Health Perspect. 2000;108:1015–1018
  34. Mandal BK, Ogra Y, Suzuki KT. Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem Res Toxicol. 2001;14:371–378
  35. Mass MJ, Tennant A, Roop BC, et al. Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol. 2001;14:355–361
  36. Petrick JS, Ayala-Fierro F, Cullen WR, et al. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol. 2000;163:203–207
  37. Zhang X, Cornelis R, De KJ, et al. Accumulation of arsenic species in serum of patients with chronic renal disease. Clin Chem. 1996;42:1231–1237
  38. Sasaki A, Oshima Y, Fujimura A. An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007;35:252–262
  39. Sinha M, Manna P, Sil PC. Arjunolic acid attenuates arsenic-induced nephrotoxicity. Pathophysiology. 2008;15:147–156
  40. Chung CJ, Huang CJ, Pu YS, et al. Urinary 8-hydroxydeoxyguanosine and urothelial carcinoma risk in low arsenic exposure area. Toxicol Appl Pharmacol. 2008;226:14–21
  41. Bongiovanni GA, Soria EA, Eynard AR. Effects of the plant flavonoids silymarin and quercetin on arsenite-induced oxidative stress in CHO-K1 cells. Food Chem Toxicol. 2007;45:971–976
  42. Hsueh YM, Wu WL, Huang YL, et al. Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis. 1998;141:249–257
  43. Hsueh YM, Chiou HY, Huang YL, et al. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev. 1997;6:589–596

 Originally published online as doi: 10.1053/j.ajkd.2009.06.016 on August 17, 2009.

PII: S0272-6386(09)00879-8

doi: 10.1053/j.ajkd.2009.06.016

American Journal of Kidney Diseases
Volume 54, Issue 5 , Pages 859-870 , November 2009

Article Tools

* Image Usage & Resolution